Skip to main content
SpringerLink
Log in

miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447. https://doi.org/10.1182/blood-2016-08-733196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cazzola M (2020) Myelodysplastic syndromes. N Engl J Med 383:1358–1374. https://doi.org/10.1056/NEJMra1904794

    Article  CAS  PubMed  Google Scholar 

  3. Patnaik MM, Tefferi A (2020) Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol 95:97–115. https://doi.org/10.1002/ajh.25684

    Article  CAS  PubMed  Google Scholar 

  4. Gordon JE, Wong JJ, Rasko JE (2013) MicroRNAs in myeloid malignancies. Br J Haematol 162:162–176. https://doi.org/10.1111/bjh.12364

    Article  CAS  PubMed  Google Scholar 

  5. Di Leva G, Garofalo M, Croce CM (2014) MicroRNAs in cancer. Annu Rev Pathol 9:287–314. https://doi.org/10.1146/annurev-pathol-012513-104715

    Article  CAS  PubMed  Google Scholar 

  6. Hatzl S, Perfler B, Wurm S, Uhl B, Quehenberger F, Ebner S, Troppmair J, Reinisch A, Wölfler A, Sill H, Zebisch A (2020) Increased expression of micro-RNA-23a mediates chemoresistance to cytarabine in acute myeloid leukemia. Cancers (Basel) 12:496. https://doi.org/10.3390/cancers12020496

    Article  CAS  Google Scholar 

  7. Hatzl S, Geiger O, Kuepper MK, Caraffini V, Seime T, Furlan T, Nussbaumer E, Wieser R, Pichler M, Scheideler M, Nowek K, Jongen-Lavrencic M, Quehenberger F, Wolfler A, Troppmair J, Sill H, Zebisch A (2016) Increased expression of miR-23a mediates a loss of expression in the RAF kinase inhibitor protein RKIP. Cancer Res 76:3644–3654. https://doi.org/10.1158/0008-5472.CAN-15-3049

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Caraffini V, Geiger O, Rosenberger A, Hatzl S, Perfler B, Berg JL, Lim C, Strobl H, Kashofer K, Schauer S, Beham-Schmid C, Hoefler G, Geissler K, Quehenberger F, Kolch W, Athineos D, Blyth K, Wolfler A, Sill H, Zebisch A (2020) Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica 105:375–386. https://doi.org/10.3324/haematol.2018.209650

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zebisch A, Lal R, Muller M, Lind K, Kashofer K, Girschikofsky M, Fuchs D, Wolfler A, Geigl JB, Sill H (2016) Acute myeloid leukemia with TP53 germ line mutations. Blood 128:2270–2272. https://doi.org/10.1182/blood-2016-08-732610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C, Wolfler A, Hoefler G, Sill H, Zebisch A (2018) Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma 59:501–504. https://doi.org/10.1080/10428194.2017.1339879

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by research funding from the Austrian Society of Internal Medicine (Joseph-Skoda Awards to A. Zebisch and A. Reinisch) and the Austrian Science Fund (grants P 31430–458 B26 to H. Sill and P32783 to A. Reinisch). Research in the laboratories of A. Zebisch, A. Wölfler, and H. Sill is further supported by Leukämiehilfe Steiermark. A. Reinisch was also supported by the Austrian Society of Hematology and Medical Oncology (Clinical Research Grant) and MEFOgraz. PhD candidate J.L. Berg received funding from the MUG within the PhD program Molecular Medicine.

Author information

Authors and Affiliations

  1. Division of Hematology, Medical University of Graz, Auenbruggerplatz 38, 8036, Graz, Austria

    Marie-Christina Mayer, Johannes Lorenz Berg, Bianca Perfler, Stefan Hatzl, Andreas Reinisch, Albert Wölfler, Heinz Sill & Armin Zebisch

  2. Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Auenbruggerplatz 2, 8036, Graz, Austria

    Sereina Annik Herzog, Gerhard Bachmaier & Andrea Berghold

  3. Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Universitätsplatz 4, 8010, Graz, Austria

    Armin Zebisch

Authors
  1. Marie-Christina Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Lorenz Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bianca Perfler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefan Hatzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sereina Annik Herzog
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerhard Bachmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Berghold
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Reinisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Albert Wölfler
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Heinz Sill
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Armin Zebisch
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.C.M., J.L.B., B.P., S.H., and A.Z. performed the research; A.R., A.W., H.S., and A.Z. contributed essential reagents, tools, or patient specimens; M.C.M., J.L.B., S.H., A.R., and A.Z. analyzed the data; S.A.H., G.B., and A.B. performed the statistical analyzes; M.C.M. and A.Z. wrote the manuscript; all authors read the manuscript and/or revised it critically; A.Z. designed the research study; all authors approved the submitted and final version.

Corresponding author

Correspondence to Armin Zebisch.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of the Medical University of Graz (EK 30–464 ex 17/18). Informed consent was obtained from all patients for being included in the study.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

A.R.: research support from Celgene/BMS; A.W.: research support from Celgene/BMS. Honoraria for lectures from Celgene/BMS, Novartis, Ariad, Pfizer and Astellas. H.S.: Consultancy for Celgene/BMS and AbbVie; A.Z.: Consultancy for Celgene/BMS. Participation in Advisory boards for AbbVie and Novartis. Honoraria for lectures from Novartis; all other authors declare no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 205 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mayer, MC., Berg, J.L., Perfler, B. et al. miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. Ann Hematol 100, 2845–2847 (2021). https://doi.org/10.1007/s00277-021-04598-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04598-6

Search

Navigation